Zimmer Biomet Q3 sales beat estimates, raises FY outlook
ZBH•Zimmer Biomet reported Q3 sales of $2.06 billion and adjusted EPS of $1.90, both above analyst estimates. It raised its 2026 revenue growth and adjusted diluted EPS outlook.
1. Quarterly results
Q3 net sales rose 3.1% to $2.06 billion, slightly above the $2.04 billion analyst estimate. Adjusted EPS was $1.90, compared with the $1.88 estimate, and was flat year over year.
2. Raised 2026 outlook
Zimmer Biomet raised its 2026 constant-currency revenue growth forecast to 4.1%-4.6% from 3.4%-4.4%, and its organic constant-currency growth forecast to 3.0%-3.5% from 2.25%-3.25%. It now expects adjusted diluted EPS of $8.50-$8.60, up from $8.47-$8.59.
3. Performance drivers
The company cited growth in Hips, S.E.T., Technology & Data, Bone Cement and Surgical franchises, broad-based performance across business segments, and U.S. commercial transformation efforts.
